Table 1 Baseline patient characteristics according to the expression level of HSPA8 in TCGA CN-AML patients
From: High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia
Group | Cohort | P | |
|---|---|---|---|
HSPA8high | HSPA8low | ||
Total | 38 | 39 | Â |
Age | |||
 ≥ 60y | 22 | 20 | 0.649 |
 < 60y | 16 | 19 |  |
Sex | |||
 Male | 18 | 24 | 0.256 |
 Female | 20 | 15 |  |
FAB classification | |||
 M0 | 0 | 6 | 0.036 |
 M1 | 13 | 7 | 0.172 |
 M2 | 13 | 7 | 0.172 |
 M3 | 0 | 0 | 0.999 |
 M4 | 4 | 15 | 0.01 |
 M5 | 7 | 3 | 0.289 |
 M6 | 0 | 1 | 0.999 |
 M7 | 1 | 0 | 0.999 |
Clinical characteristics (mean(SD)) | |||
 BM blast (%) | 42.84(33.17) | 38.87(20.43) | 0.792 |
 WBC (×10^9) | 36.62(36.52) | 46.21(48.25) | 0.334 |
 Hemoglobin (g/L) | 9.47(1.62) | 9.92(1.35) | 0.2 |
 Platelet (×10^9) | 80.46(66.98) | 66.47(48.11) | 0.303 |
Mutation | |||
 FLT3 | 22 | 5 | < 0.0001 |
 IDH1 | 7 | 13 | 0.194 |
 IDH2 | 4 | 8 | 0.227 |
 KRAS | 2 | 1 | 0.982 |
 CEBPA | 4 | 4 | 0.999 |
 TET2 | 5 | 3 | 0.68 |
 TP53 | 1 | 0 | 0.99 |
 NRAS | 2 | 2 | 0.999 |
 RUNX1 | 2 | 9 | 0.056 |
 NPM1 | 16 | 22 | 0.301 |